A new GLP-1 receptor agonist pill outperformed oral semaglutide (Rybelsus) in improving blood glucose levels in adults with type 2 diabetes not adequately controlled on metformin. The phase III ACHIEVE-3 study showed these results.[1] The primary goal was to monitor the reduction of HbA1c level, an indicator of long-term blood sugar level. Patients on the new drug achieved greater improvement in glucose control than those on semaglutide. This drug belongs to the group of GLP-1 agonists, similar to semaglutide.[1] The study included adult patients with poorly controlled type 2 diabetes on metformin. The results confirm the higher efficacy of the new pill compared to the existing oral semaglutide.[1]